Recent studies that have shown that blocking glycolytic commitment by pretreating T cells with 2-deoxy glucose (2-DG) also renders the T cells with reduced IFNγ secreting ability, but improved in vivo survival and tumor control [39]. This evidence concerns the gene IFNG and neoplasm.